Thrombotic thrombocytopenic purpura (TTP) is a disorder of the blood-coagulation system, causing extensive microscopic clots to form in the small blood vessels throughout the body. TTP is quite a rare pathology in childhood, being more frequent among adults. Often it is hardly to distinguish from other haematological pathologies in children both for its uncommon incidence and for the presence of clinical forms that are heterogeneous and difficult to classify. We report the case of an ll-year-old girl suffering from TTP, in whom the study of metallo-protease ADAMST 13 showed a low value « 10%) with positive anti-ADAMTS 13 Ig G and inhibitor, strengthening the hypothesis of autoimmune genesis. The girl was initially treated with cycles of plasmapheresis with both poor compliance and benefit for the girl and later treated with IV Immunoglobulin. This last treatment resulted in a rapid improvement of the symptomatology and no reappearance of the clinical signs at four-year follow-up. Thrombotic thrombocytopenic purpura (TTP), first reported by Moschowitz in 1924, is characterized by multifocal stroke episodes caused by occlusions scattered at microcirculatory level, thrombocytopenia from consumption and haemolytic anemia from mechanical damage with presence of schistocytes and negative Coombs test (1, 2). Fever, neurological and renal involvements may also be present. It is classified as primary or secondary and can manifest itself both as oligosymptomatic form and as very perilous form that can lead the subject to coma and death (2).
TTP is a rare disease, and has been reported to affect 3.7 individuals per one million annually in the United States (2) . In children it is often hardly distinguishable from other haematological pathologies with which it can be mistaken, like haemolytic-uremic syndrome, and this difficulty is due to two main factors: poor incidence of TTP, which makes it little known, and the presence of clinical forms that are very heterogeneous and not easily classified.
Most cases of TTP arise from inhibition of the enzyme ADAMTS 13, a metalloprotease responsible for cleaving large multimers of von Willebrand factor(vWF) into smaller units (3, 4) .
Apart from plasmapheresis, immunosuppressants, such as glucocorticoids, rituximab, cyclo phosphamide, vincristine, or cyclosporine may also be used if there is a relapse or recurrence following plasmapheresis (3) (4) (5) (6) (7) . Here we report on a II-year-old girl who came to our observation in whom the treatment with Intravenous immunoglobulin (IVIG) resulted in a rapid resolution of the symptomatology.
Case report
An l l-year-old girl, second born from unrelated parents, had been born after a spontaneous full term delivery following a normal pregnancy. The mother has referred to be affected by hepatitis B, otherwise the family history is irrelevant. Birth-weight was 3500 grams. No anomalies were reported in the perinatal period and the acquisition offirst milestones were normal. The girl was admitted to our attention for the presence of marked sclera and skin icterus, and limb hematoma. The parents referred that about three weeks prior to admission, the girl had begun to show lower limb hematoma, followed by upper limb hematoma; for this reason she was taken to the family doctor who suggested to carry out haematological exams which showed severe thrombocytopenia (I5x I01\3). The patient was sent to the transfusional centre in Ragusa and then hospitalized in the Paediatrics Unit, in Ragusa, for clinical tests and the treatment. Except for the skin and sclera icterus, and the limb hematoma, no anomalies were found at the physical examination, including spleen and liver size.
The haematochemical tests showed: platelets 11.000/mm3, red blood cells 3. Hormonal thyroid values were normal with absence of anti-thyroglobulin antibodies. Abdomen ultrasonography and CT scan, performed with contrast, showed a nonnalliver, biliary ducts and gall bladder not swollen, kidneys in the right position, of normal size for the age. Diagnosis of thrombocytic thrombocytopenia purpura was given. Daily therapy with plasmapheresis was started, together with Methylprednisolone (40 mg x 2 intravenously), and Dipyridamole. After a period of improvement, a week after the critical phase, the girl manifested recurrence of crises with bilateral limb hematoma. The haematochemical tests showed the presence of thrombocytopenia (33x I0"3), anemia (red blood cells 2.6 x 10"6; haemoglobin (9.7 g/I), reticulocytosis (5.55%, n.v. 0,2-2%), with high values of total and indirect bilirubin (4.3 and 3,3 mg/dl respectively) and LDH of 744L IU/l. A week after the resolution of the first recurrence there was a similar episode, but with a cutaneous nonvescicular rash on the face and trunk. On this occasion haematochemical tests showed the following values: platelets 117.000/mm3, red blood cells 2.0 xlO"6/ mrri', haemoglobin 7.6 g/mm', reticulocytosis (6%) total bilirubin 2.7 mg/dl, with indirect 2.10 mg/dl, and LDH 778 IU/l. Two weeks later the girl had a sudden fever attack with increased indexes of inflammation and a positive blood culture for Serratia macescens. A culture of the material taken from the point of venous catheter was positive for Staphylococcus epidermidis. An antibiotic treatment with Netilmicin was started with an improvement of the clinical picture. After a week there was a third recurrence; the tests on this occasion showed the following data: platelets 33.000/mm3, red blood cells 2.2xI0"6, haemoglobin 8.2 g/dl, reticulocytosis 6.2%, total bilirubin 2 mg/dl, indirect bilirubin 1.5 mg/dl, LDH 495 IU/I (Table II) . After a further worsening, (platelets 50.000/mm 3 ) , there was an improvement of the clinical picture. During the stay in hospital the girl also showed depressive psychological troubles because of the bad compliance of the disease, and for the long stay in the hospital, which required psychological treatment. The episodes of lipothymia and epistaxis that occasionally had manifested during the stay in hospital did not appear again. The study of ADAMST 13 activity showed a severe low value «10%) with positive anti-ADAMTS 13 IgG and inhibitor.
The patient was dismissed with improvement of clinical conditions and normalization of haematochemical tests. After one month, anemia and hyperbilirubinemia appeared again. The haematochemical tests showed the presence of thrombocytopenia (33x I0"3), anemia (red blood cells 2.6 x 10"6; haemoglobin (8.1 g/dl,), reticulocytosis (4.97%), with high values of bilirubin total (3.8 mg/dl) and indirect (2.9 mg/dl) and LDH of 732 IU/l. The patient over-all underwent 32 sessions of plasmapheresis. Following this session some nettlerash manifestations appeared, which disappeared without further complications.
In view of the poor compliance and poor efficacy of the plasmapheresis in the girl, IVIG therapy was started at the dosage of two grams/kg/day for two consecutive days which resulted in a rapid resolution of her haematological test and an improvement of the general condition within 10 days. After six months the study of ADAMST 13 activity was normal (110%) anti ADAMTS 13 Ig G and inhibitor were not detected. The girl was followed-up every 3-6 months for four years and no other episodes were referred.
DISCUSSION
TTP has been studied for a long time in order to find out its pathogenesis, and in recent years much progress has been made in this field. The anomaly lies in the deficit of ADAMST 13 and/or in the presence of antibodies that inhibit the activity of this enzyme (8, 9) . The deficit of this enzyme may be related to an inherited gene defect (2-3% of the cases) or more frequently to the secondary development of anti-ADAMST 13 antibodies which act neutralizing the enzymatic activity and/or accelerating protease removal from the circulation (9) .
ADAMSTI3 is a metalloprotease, synthesized at hepatic level, whose substrate is represented by Von Willebrand's factor, a multimeric that is essential in forming the platelet thrombi. It adheres to the endothelial cells and to the vessel walls and the circulating platelets adheres to it through a glycoprotein of a membrane called Gpl30-like receptor (G PL). This process needs a modulation and this role iscarriedout by metalloproteaseADAMST 13 that eliminates the Von Willebrand factor in excess limiting the uncontrolled growth of the platelet thrombi. Its deficiency, as it happens in presence of autoinhibitor antibodies, or its malfunction or in the even rarer case of genetic anomalies causes the uncontrolled growth of thrombi at peripheral level. This process is at the basis of thrombocytopenia from consumption and of haemolytic anemia from mechanical damage and can cause vessel occlusions followed by ischemia at different organ levels. In TTP the central nervous system is a vulnerable organ and neurological damage is considered a relevant sign in defining this affection. Another organ which is exposed to functional damage, even severe, is the kidney, which is also frequently observed in the haemolytic-uremic syndrome (HUS) (8) (9) . An important aspect is also the evaluation of the hepatic functionality. In fact, as already stated, metalloprotease 13 is mostly synthetized in the liver, therefore hepatic involvement may be present ( I0).
The current prevailing opinion is that, while undetectable or very low plasma levels of enzymatic activity (less than 10%) allow a diagnosis of inherited or acquired TTP, not all patients on the basis of haematologic clinical and laboratory signs and symptoms are properly diagnosed. The cases of TTP more frequently associated with normal or moderately reduced ADAMTS 13 (between 10% and 40% of normal) are TTP secondary to other diseases or conditions, such as allogenic bone marrow transplantation, HIV infection, chemotherapy and metastatic cancer. Thrombotic microangiopathies other than TTP (typically colitis-associated HUS) have normal or only moderately reduced levels of ADAMTS 13 (9) (10) (11) ).
An important practical problem for the clinician is whether or not ADAMTS 13 testing during the acute phase of TTP helps to monitor plasma therapy (infusion or exchange) and to predict such important short-term outcomes as clinical and laboratory remission or mortality. Most studies that have attempted to monitor ADAMTS 13 levels (and sometime anti-ADAMTS 13) at regular intervals during treatment with plasmapheresis do not provide convincing evidence that real-time ADAMTS 13 testing helps to improve the management of patients with acquired TTP (9-11). Most of the studies in literature show that most patients with anti-ADAMTS 13 need more exchange sessions to achieve remissions than those without antibodies (9) .
Some infections may present with haematologic manifestations similar to TTP. Idiopathic Thrombocytopenic Purpura (lTP) is characterized by low platelet count with otherwise normal results on complete blood count and peripheral blood smear. It is an isolated thrombocytopenia with no other underlying aetiology. ITP is caused by autoantibodies against platelets and antigenic target in most patients appears to be the platelet glycoprotein lIb/IlIa complex. Sequential occurrence of TTP to essential thrombocytopenia and ITP has been reported (12) . Disseminated Intravascular Coagulation (DIC) differs from TTP since in it the activation of coagulation factors is prevalent, instead of platelet aggregation, with consumption of these factors and consequent extension of Prothrombin Time (PT) and of Plasma Thromboplastin Time (PTT). HUS differs from TTP for the presence of previous haemorrhagic diarrhoea often caused by strains of E. coli producers of Shiga-like toxins that are responsible for endothelial damage and is characterized by severe damage of kidney functionality; besides, there is mild thrombocytopenia and hemolytic anemia and no report of ADAMSTl3 deficiency. The atypical form of HUS presents the same clinical characteristics as the typical form, but it differs from it for the pathogenesis which consists in a deficiency of the regulation factors of the complement and for the fact that it is not associated to previous diarrhoea (9) . The distinction ofthese forms is important for the clinical and therapeutic approach.
Morishima et al. report the case of an l l-year-oldgirl who was diagnosed with TTP because she had decreased ADAMTS 13 activity and a measurable level of the ADAMTS 13 inhibitor. The patient was successfully treated by plasmapheresis (10) .
The idiopathic TTP usually responds well to the plasmapheresis treatment to which immunosuppressant medication is often associated. Plasmapheresis treatment allows the removal of the autoantibodies and the reactivation of the quantity of ADAMSTl3. Immunosuppressant drugs are necessary for the modulation of antibody activity, reducing also the production of antibodies against ADAMSTl3. Secondary forms of TTP are treated according to the underlying pathology. Treatment of TTP in children is controversial (13) (14) (15) . Immunosuppressant drugs such as glucocorticoids, rituximab, cyclophosphamide, vincristine, or cyclosporine may also be used if there is relapse or recurrence following plasmapheresis (5-7), but there are no data from the literature to confirm this utilization in childhood; in our patient treatment with IVIG was effective and more active than plasmpapheresis.
In our patient, the ADAMSTl3 was low and the ADAMSTl3 IgG antibodies and inhibitors confirmed the autoimmune genesis. Neither neurologic nor renal involvement monitored through haematochemical tests were reported, the latter being further confirmed by abdomen ultrasound and CT scan investigation Treatment of young TTP patients with plasmapheresis is usually applied but this kind of treatment is not always effective and it is not easily accepted by the young patients. On the other hand, other types of treatment in young patients including suppressant drugs and IVIG are controversial. We want to underline the excellent results obtained in this girl with IVIG treatment in whom cycles of plasmapheresis treatment had been poorly effective. The use of IVIG in young patients with TTP is not frequently reported (9) but our girl responded well to this kind of treatment with an improvement of her clinical signs and general conditions without any recurrence in the following four years. Treatment with IVIG resulted more effective in solving the clinical feature shown by the patient than the repeated cycles of treatment with plasmapheresis.
In conclusion, when approaching a thrombocytopenic patient who is also affected by haemolytic anemia, it is important to pay particular attention to the clinical characteristics that may allow to state the aetiology, to make a correct diagnosis, to establish correct treatment. Recurrence of the symptomatology in TTP patients, even after many years, is not uncommon especially in association with other autoimmune pathologies (like systemic lupus erythematous). Of course more studies need to be carried out to understand why some children respond to the conventional therapy and others not, and to better clarify which children may respond better to IVIG therapy.
